KIT and gastrointestinal stromal tumor: Malfunctions of Kit acquired by overexpression or mutations have been associated with several diseases, including gastrointestinal stromal tumors (GIST), mastocytosis, and acute myelogenous leukemia (AML) [143,144,145], and although the kinase inhibitor Imatinib (Glivec) has been successfully developed as an FDA-approved drug for GIST, long-term exposure often causes secondary mutations at exons 13, 14, or 17, which encode tyrosine kinase domains [146].